Form D · Biotechnology

Bonti, Inc.

Newport Beach, CA · CIK 0001650638

Offering snapshot reported Feb 2, 2018 · SEC filing

Reported sold
$15.5M
Offering amount: $15.5M
Investors reported
53
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 19, 2018
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 2, 2018Initial$15,463,786No comparison53SEC filing
Apr 19, 2017Amendment$11,706,516$6,685,007vs Jan 4, 201732SEC filing
Jan 4, 2017Initial$5,021,509No comparison20SEC filing
Sep 15, 2015Amendment$8,839,004$3,757,894vs Aug 13, 201539SEC filing
Aug 13, 2015Initial$5,081,110No comparison34SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0 (estimated)
Finders' fees
$0
Form D file number
021-304714

Source: Form D, filed Feb 2, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Kenton Barry Abel Executive
Wajdie Ahmad Executive
Tom Albright Director
Leonard Brandt Director
Fauad Hasan Director, Executive
Dennis Huang Director
Michael Jarpe Executive
Alexey Konov, Ph.D. Director
Jonathan Lim, M.D. Director
David Ramsay Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
4921 Birch St. Suite 120
Newport Beach, CA, 92660